Takeda Pharmaceutical Company Limited (LON:0A87)

London flag London · Delayed Price · Currency is GBP · Price in USD
18.04
0.00 (0.00%)
At close: Feb 10, 2026
Market Cap43.76B +29.8%
Revenue (ttm)21.16B -2.5%
Net Income535.14M -45.7%
EPS0.33 -45.9%
Shares Outn/a
PE Ratio81.76
Forward PEn/a
Dividend0.43 (2.38%)
Ex-Dividend DateSep 30, 2025
Volume9
Average Volume973
Open18.04
Previous Closen/a
Day's Range18.04 - 18.04
52-Week Range13.93 - 18.04
Betan/a
RSI73.57
Earnings DateJan 29, 2026

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange London Stock Exchange
Ticker Symbol 0A87
Full Company Profile

Financial Performance

In fiscal year 2025, LON:0A87's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements